Fifth, the Commission assessed the capacity of strain banks and investigated
whether the combination of the Parties’ strain banks would be unmatched by rivals and would raise a barrier to innovation. While Novozymes’ existing bank has c. [a number] physical strains and Chr. Hansen’s [a number] deposits (which Chr.
Hansen estimates would equate to c.[a number] strains), the Parties’ strain banks are largely differentiated in composition. Novozymes’ bank is focused on [information on strain banks] while Chr. Hansen’s is focused on [information on strain banks] given its dairy heritage.341 The results of the market investigation revealed that other competitors will have comparable strain banks and strain engineering capabilities; and the Parties can and do innovate based on publicly available genomes and strain banks.342 The Commission did not find any indications that a combination of the two complementary strain banks would create a competitive advantage that would negatively impact the overall innovation competition on the market. Moreover, publicly available sequences vastly outweigh the Parties’ sequences.